EA201400879A1 - Производные тетрагидрохиназолинона в качестве ингибиторов tank и parp - Google Patents

Производные тетрагидрохиназолинона в качестве ингибиторов tank и parp

Info

Publication number
EA201400879A1
EA201400879A1 EA201400879A EA201400879A EA201400879A1 EA 201400879 A1 EA201400879 A1 EA 201400879A1 EA 201400879 A EA201400879 A EA 201400879A EA 201400879 A EA201400879 A EA 201400879A EA 201400879 A1 EA201400879 A1 EA 201400879A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tetrahydrohinazolinon
derivatives
tank
parp inhibitors
inhibitors
Prior art date
Application number
EA201400879A
Other languages
English (en)
Other versions
EA026611B1 (ru
Inventor
Ханс-Петер Бухшталлер
Кристина Эсдар
Биргитта Лойтнер
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201400879(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201400879A1 publication Critical patent/EA201400879A1/ru
Publication of EA026611B1 publication Critical patent/EA026611B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Соединения формулы Iв которой U, V и W имеют значения, указанные в п.1, являются ингибиторами Танкиразы и могут применяться, в частности, для лечения заболеваний, таких как злокачественное новообразование, сердечно-сосудистых заболеваний, поражений центральной нервной системы и различных форм воспаления.
EA201400879A 2012-02-09 2013-01-14 Производные тетрагидрохиназолинона в качестве ингибиторов tank и parp EA026611B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12000841 2012-02-09
PCT/EP2013/000078 WO2013117288A1 (en) 2012-02-09 2013-01-14 Tetrahydro-quinazolinone derivatives as tank and parp inhibitors

Publications (2)

Publication Number Publication Date
EA201400879A1 true EA201400879A1 (ru) 2015-01-30
EA026611B1 EA026611B1 (ru) 2017-04-28

Family

ID=47628092

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400879A EA026611B1 (ru) 2012-02-09 2013-01-14 Производные тетрагидрохиназолинона в качестве ингибиторов tank и parp

Country Status (32)

Country Link
US (1) US9339503B2 (ru)
EP (1) EP2812323B1 (ru)
JP (1) JP6116592B2 (ru)
KR (1) KR20140121477A (ru)
CN (1) CN104093714B (ru)
AR (1) AR089944A1 (ru)
AU (1) AU2013218357B2 (ru)
BR (1) BR112014019357A8 (ru)
CA (1) CA2863991C (ru)
CL (1) CL2014002097A1 (ru)
CO (1) CO7020919A2 (ru)
DK (1) DK2812323T3 (ru)
EA (1) EA026611B1 (ru)
EC (1) ECSP14017586A (ru)
ES (1) ES2579980T3 (ru)
HK (1) HK1202551A1 (ru)
HR (1) HRP20160735T1 (ru)
HU (1) HUE029717T2 (ru)
IL (1) IL233984A (ru)
MX (1) MX349736B (ru)
NZ (1) NZ630170A (ru)
PE (1) PE20141823A1 (ru)
PH (1) PH12014501581A1 (ru)
PL (1) PL2812323T3 (ru)
PT (1) PT2812323T (ru)
RS (1) RS55377B1 (ru)
SG (1) SG11201404654SA (ru)
SI (1) SI2812323T1 (ru)
TW (1) TWI572593B (ru)
UA (1) UA116627C2 (ru)
WO (1) WO2013117288A1 (ru)
ZA (1) ZA201406579B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302358B (zh) 2012-03-07 2017-12-05 癌症研究协会:皇家癌症医院 3‑芳基‑5‑取代的异喹啉‑1‑酮化合物和它们的治疗用途
WO2014036022A1 (en) * 2012-08-29 2014-03-06 Amgen Inc. Quinazolinone compounds and derivatives thereof
BR112015012425A2 (pt) 2012-12-31 2017-07-11 Cadila Healthcare Ltd composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto
AU2014320149A1 (en) 2013-09-11 2016-04-07 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
AU2014347126A1 (en) 2013-11-07 2016-04-28 Eli Lilly And Company Pyrido[2,3-d]pyrimidin-4-one compounds as tankyrase inhibitors
CN106243088B (zh) 2015-06-03 2019-01-04 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途
KR101777475B1 (ko) * 2015-12-08 2017-09-11 에스티팜 주식회사 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
ES2874185T3 (es) 2016-06-30 2021-11-04 Riken Nuevo compuesto o una sal farmacéuticamente aceptable del mismo
CN108727302A (zh) * 2017-10-23 2018-11-02 科迈化工股份有限公司 一种环保型n-叔丁基-2-苯并噻唑次磺酰胺（ns）合成工艺
US11566017B2 (en) 2017-12-27 2023-01-31 Riken Dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor
JP7369968B2 (ja) * 2017-12-27 2023-10-27 公益財団法人がん研究会 抗がん剤
EP3746436A4 (en) 2018-08-16 2022-03-16 F. Hoffmann-La Roche AG CONDENSED CYCLIC COMPOUNDS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0880508B1 (en) 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
JP4969443B2 (ja) * 2004-06-30 2012-07-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキナゾリノン誘導体
ES2359931T3 (es) 2005-03-11 2011-05-30 Merck Patent Gmbh Tetrahidro- y dihidroquinazolinonas.
ES2381446T3 (es) 2007-03-08 2012-05-28 Janssen Pharmaceutica, N.V. Derivado de quinolinona como inhibidores de PARP y TANK
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2011111880A1 (ko) * 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물

Also Published As

Publication number Publication date
WO2013117288A1 (en) 2013-08-15
CO7020919A2 (es) 2014-08-11
WO2013117288A8 (en) 2014-07-31
CN104093714A (zh) 2014-10-08
SG11201404654SA (en) 2014-09-26
CL2014002097A1 (es) 2014-11-07
HK1202551A1 (zh) 2015-10-02
AR089944A1 (es) 2014-10-01
PL2812323T3 (pl) 2016-09-30
JP2015506965A (ja) 2015-03-05
US9339503B2 (en) 2016-05-17
ES2579980T3 (es) 2016-08-18
IL233984A (en) 2017-09-28
PE20141823A1 (es) 2014-11-29
HUE029717T2 (en) 2017-03-28
PH12014501581B1 (en) 2014-10-08
EP2812323B1 (en) 2016-04-06
PT2812323T (pt) 2016-07-13
DK2812323T3 (en) 2016-05-09
PH12014501581A1 (en) 2014-10-08
TWI572593B (zh) 2017-03-01
CA2863991C (en) 2020-08-11
RS55377B1 (sr) 2017-03-31
US20150025071A1 (en) 2015-01-22
ECSP14017586A (es) 2015-09-30
AU2013218357B2 (en) 2017-01-05
ZA201406579B (en) 2015-12-23
UA116627C2 (uk) 2018-04-25
EA026611B1 (ru) 2017-04-28
NZ630170A (en) 2016-03-31
CN104093714B (zh) 2016-08-24
TW201336828A (zh) 2013-09-16
CA2863991A1 (en) 2013-08-15
MX2014009491A (es) 2014-08-29
JP6116592B2 (ja) 2017-04-19
BR112014019357A8 (pt) 2017-07-11
KR20140121477A (ko) 2014-10-15
SI2812323T1 (sl) 2016-08-31
MX349736B (es) 2017-08-10
AU2013218357A8 (en) 2015-01-22
BR112014019357A2 (ru) 2017-06-20
AU2013218357A1 (en) 2014-09-25
EP2812323A1 (en) 2014-12-17
HRP20160735T1 (hr) 2016-07-29

Similar Documents

Publication Publication Date Title
EA201400879A1 (ru) Производные тетрагидрохиназолинона в качестве ингибиторов tank и parp
EA201401212A1 (ru) Производные пирролотриазинона
EA201401062A1 (ru) Бициклические пиразиноновые производные
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
EA201301302A1 (ru) Производные пиридина и пиразина
EA201590230A1 (ru) Соединения пиразолопиримидина в качестве ингибиторов киназ
EA201301301A1 (ru) Производные тиазола
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
MX362939B (es) Derivados de (aza-)isoquinolinona.
EA201300730A1 (ru) Производные индазолилтриазола
EA201490537A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ C-Kit
MX359656B (es) Derivados de oxoquinazolinil-butanamida.
MX2016001134A (es) Derivados 1,3-disustituidos de ciclopentano.
MX2016014436A (es) Derivados de heterociclil-butanamida.
MX364859B (es) Derivados de imidazopirazinona.
EA201200087A1 (ru) 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k
MX2016001536A (es) Derivados de urea de piperidinas.
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
EA201590656A1 (ru) Азаиндолины
EA201101042A1 (ru) Производные бензотиазолона

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU